Podcasts about rociletinib

  • 3PODCASTS
  • 30EPISODES
  • 6mAVG DURATION
  • ?INFREQUENT EPISODES
  • Apr 20, 2016LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about rociletinib

Latest podcast episodes about rociletinib

GRACEcast
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib
GRACEcast ALL Subjects audio and video
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib
GRACEcast Lung Cancer Video
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 20, 2016 5:20


Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib
GRACEcast ALL Subjects audio and video
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast Lung Cancer Video
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast
Third Generation EGFR TKIs for Acquired Resistance

GRACEcast

Play Episode Listen Later Feb 17, 2016 3:07


Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib
GRACEcast
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast ALL Subjects audio and video
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast Lung Cancer Video
Treatment Options for EGFR T790M Negative Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 9, 2016 24:36


Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

GRACEcast
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast ALL Subjects audio and video
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast Lung Cancer Video
Emerging Options for T790M-Positive Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 8, 2016 13:53


positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib
GRACEcast
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast ALL Subjects audio and video
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast Lung Cancer Video
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 12, 2015 3:28


Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

GRACEcast ALL Subjects audio and video
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast Lung Cancer Video
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

GRACEcast

Play Episode Listen Later Dec 8, 2015 3:25


Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

GRACEcast Lung Cancer Video
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast ALL Subjects audio and video
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 7, 2015 3:28


Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

GRACEcast Lung Cancer Video
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast ALL Subjects audio and video
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 20, 2015 3:24


Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

GRACEcast Lung Cancer Video
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast ALL Subjects audio and video
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 12, 2015 5:09


Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

GRACEcast Lung Cancer Video
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib
GRACEcast
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib
GRACEcast ALL Subjects audio and video
The Potential Value of Repeat Biopsies in Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 25, 2015 2:19


MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib